Recent research shows that the number of diseases associated with obesity has been increasing. In obese persons, association with functional constipation is noted in 24.0% of cases, and obesity is recorded in 60.0% of patients with functional constipation. Among the possible mechanisms for the development of such a combination are changes in serotonin level in the blood, although the existing data are ambiguous and sometimes controversial.
The objective of the study is to investigate the changes in serotonin level in the blood of obese patients in combination with constipation and its relationship with the lipid profile of the blood.
Materials and methods. 63 patients with obesity in combination with irritable bowel syndrome with constipation (IBSc), 24 patients with normal body mass index and 10 practically healthy people were examined. 25 patients with obesity and constipation had a body mass index of 32.8±0.24kg/m2, 28 patients – 37.8±kg/m2, and 10 patients – 42.6±0.5kg/m2. In patients with irritable bowel syndrome without obesity, the body mass index was 21.7±0.4kg/m2. The blood serotonin level and lipid profile of the blood was determined in all patients.
Results. It was deermined that in case of irritable bowel syndrome with constipation, serotonin level in the blood was reduced. In obesity with IBSc, the concentration of serotonin, on the contrary, was elevated. All patients with IBSc and obesity were marked an elevated level of total cholesterol and triglycerides. A direct correlation between high levels of triglycerides and serotonin concentration in serum of such comorbid patients was detected. The increase in the degree of obesity in the presence of IBSc was accompanied by a decrease in the concentration of cholesterol of high density lipoprotein. Patients with IBSc without excessive body weight had no such deviations.
Conclusions. With an increase in the degree of obesity, serotonin level in the blood increases and the lipid blood spectrum worsens.
Alekseeva NS, Salmina-Khvostova EV, Beloborodova EV, Koinova YA, Aslembytova AT. Indicators of the hormonal background in the violation of eating behavior in patients with metabolic syndrome. Lechashchyi vrach, 2017; 10: 92-95.
Alekseeva NS, Salmina-Khvostova OI, Beloborodova EV. Interrelation of dietary disorders with the level of melatonin and serotonin in patients with metabolic syndrome. Sibirskiy vestnik psikhiatrii i narkologii. 2015; 5: 28-32.
Anikina NV, Smirnova EN. Psycho-emotional status and serotonin levels in obese women. Sovremennyye problemy nauki i obrazovaniya, 2015;3. URL: www. Science - education.ru / 123 -19229.
Berezina MV. Mikhaleva OG. Bardimova TP. Obesity, mechanisms of development. Sibirskiy meditsinskiy zhurnal. 2012; 7: 15-18.
Bertrand RL, Senadheera S, Tanato A et al. Serotonin availability in rat colon is reduced during a Western diet model of obesity. Am. J. Physiol Gasrointest. Ziver Phisiol. 2012; 303(3):424-434. DOI: https://doi.org/10.1152/ajpgi.00048.2012 [PMid:22595993]
Brennan IM, Siemon RV, Luscomble-March ND. Effects of acute dietary restriction on gut motor, hormone and energy intake responses to duodenal fat in obese men. Int. J. Obes (Zond). 2011; 35: 448-456. DOI: https://doi.org/10.1038/ijo.2010.153 [PMid:20680017]
Cammillery M, Grudell AB. Appetite and obesity: a gastroenterologist's perspective. Neurogastroinyestinal Motil. 2007; 19: 333-341. DOI: https://doi.org/10.1111/j.1365-2982.2006.00864.x [PMid:17509015]
Crane JD. Inhibiting peripheral serotonin synthesis reduced obesity and metabolic dysfunction by promotion brow adipose tissue thermogenesis. Nat. Met. 2015; 21(2):166-172. DOI: https://doi.org/10.1038/nm.3766 [PMid:25485911 PMCid:PMC5647161]
Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. British Journal of Pharmacology. 2004; 141(8): 1285-1293. DOI: https://doi.org/10.1038/sj.bjp.0705762 [PMid:15100164 PMCid:PMC1574906]
Cerhan JR, Moore SC, Jacobs EJ et al. A pooled analysis of waist circumferens and mortality in 650000 adults. Mayo Clin.2014; 89(3): 335-345. DOI: https://doi.org/10.1016/j.mayocp.2013.11.011 [PMid:24582192 PMCid:PMC4104704]
Daniela MS, Shulkers A, Antony JM. An enteric signal regulates putative gastrointestinal presympatetic vasomotor neurons in rats. Amer J. Physiol. Regul. Integr. Comp. Physiol. 2016; 625-633.
Flegal KM, Kruszon-Moran D, Carrol MD et al. Trends in Obesity Among Adults in the United States 2005 to 2014. JAMA. 2016; 315: 2284-2291. DOI: https://doi.org/10.1001/jama.2016.6458 [PMid:27272580]
Gershon MD. Nerves, reflexes and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J.Clin.Gastroenterol. 2005; 39:184-193. DOI: https://doi.org/10.1097/01.mcg.0000156403.37240.30
Global, regional and national prevalence of overweight and obesity children and adults during 1980 - 2013: a systematic analysis for the global Burden of Disease Study, 2013. The Lancet, Early Online Publication,Di 10. 1016/S0140 - 6736 (14) 60460-8.
Hodge S, Bunting BP, Carn E et al. Obesity, Whole Blood Serotonin and Sex Differences in Healthy Volunteers. Obes. Facts. 2012; 5: 399-407. DOI: https://doi.org/10.1159/000339981 [PMid:22797367]
Khjrassani FE, Misher A, Garris S. Past and present of antiobesity agents: focus on monoamine modulators. American Society of Health System, Pharmacist. 2015; 72 (9): 697-706. DOI: https://doi.org/10.2146/ajhp140034 [PMid:25873617]
Lacy BE, Mearin F, Chey WD, Zembo AJ, Sinren M, Spiller R. Bowel disorders. Gastroenterology. 2016; 150: 1393-1407. DOI: https://doi.org/10.1053/j.gastro.2016.02.031 [PMid:27144627]
Lasebnik LB, Konev UV, New understanding of the role of microbiota in the pathogenesis of metabolic syndrome. Consilium Medicum. 2014; 8: 77-82.
Litvickii PF. Infringement of lipid metabolism. Voprosy sovremennoy pediarrii, 2012; 11-6:48.
Madrid AM, Poniachik J, Gwera R. Small intestinal clustered contractions and bacterial overgrowth: a frequent filing in obese patients. Dig. Dis. Sci. 2011; 56: 155-160. DOI: https://doi.org/10.1007/s10620-010-1239-9 [PMid:20431947]
Mitchenko EU, Mamedov MN, Kolesnik TV and others. A modern profile of risk factors for cardiovascular diseases in the urban population of Ukraine. Ukrainskiy kardiologicheskiy zhurnal, 2013,Appendix 4:Materials of the XIV Congress of Cardiologists of Ukraine:76 -83.
Mitchenko EU, Mamedov M, Kolesnik TV and others. Distribution of violations of carbohydrate metabolism in the urban population of Ukraine, depending on the degree and type of obesity. Mezdunarodnyi endokrynologicheskii jurnal, 2015; 4(68): 11-16.
Matthew F, Muldon, Rachel N Mackey, Mary T Korytko. The Metabolic Syndrom Is Assosiated with Reduced Central Serotonergic Responsitivity in Helthy Community Volunteers. The Journal of clinical Endocrinology and metabolism. 2006; 91(2): 718-21. DOI: https://doi.org/10.1210/jc.2005-1654 [PMid:16303834]
Namkung J, Kim H, Park S. Periferal Serotonin: a New Player in Systemic Energy Homeostasis. Mol. Cells. 2005; 38(12):1023-1028.
Ogden CL, Carrol MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. Jama. 2014; 26;311(8):806-814.
Panova EI, Martyshkina OV, Danylov VA. Pathology associated with obesity: frequency, nature and some mechanisms of formation. Sovmestnyye tekhnologii v meditsine. 2013; 5(2):108-110.
Phatak UP, Pashankar DS. Prevalence of functional gastrointestinal disorders in obese and overweight children. Int J. Obes (Zond); 2014 - (Epub ahead of print).
Ross A Hammond,Ruth Levine. The economic impact of obesity in the United States. PMC, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010.
Rossyhina OA. Effect of serotonin on psychological status in patients with irritable bowel syndrome. Novosti Meditsiny i farmatsii. Gastroyenterologiya, 2010;313:N.
Samsonov AA, Kutcherjavyj UA, Andrejev NG. Chronic constipation: problems of therapy. Vrach. 2011; 4: 24-29.
Song HJ. Constipation in community dwellings elders: prevalens and associated factors. J. Wound. Ostomy Continence Nurs. 2012; 39(6):640-645. DOI: https://doi.org/10.1097/WON.0b013e31826a4b70 [PMid:22948493]
Scholler D. The Challenge of Obesity in the WHO European Region and the Strategies for Respons. Medicine Science in Sports Exercise. 2008; 40(3); 590 oloi 10. 1249/mgs Ob 013c 318164 F 33c.
Shulpekova UO, Komova AG. Constipation in endocrine diseases. RISGGK, 2013;2;XXIII:79-85.
Symonenkov AP. Application of serotonin adipinate for the restoration of impaired smooth muscle function in surgical and therapeutic patients. Fedorov VD, Klugev VM, Ardashev VN. Vestnik intensivnoy terapii. 2005;1:1-6.
Stasi C, Bellini M, Gambaccini D, Duranti E, de Bartoli I, Fani B, Acbano E, Russo S, Sudano I, Laffi G, Taddei S, Marchi S, Bruno RM. Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients. A Pilot Study, J. Neurogastroenterol Motil. 2017;30;23(3):428-434. //Doi: 105056/ jnm 16155.
Verbovoi AF, Dolgish UA, Mitromina EV. Some aspects of the pathogenesis of pubertal obesity. Practicheskaya Medicina. 2014; 9(85):42-45.
Vd. Baan - Slotweg OH, Ziem O, Bekkali N al. Constipation and colonic transit times in children with morbid obesity. J. Pediatr. Gastroenteral. and Nutr. 2012; 52:442-445.
Vilhema E, Pais-Ribeiro J, Silva I. Predictors of Quality of life in Portuguese Obese patients: a structural equation modeling application. J. Obes. 2014; 684919.
Yablochkina TO, Pigarova EA. Hyperphagia and Obesity. Obesity and Metabolism. 2013;1:14-17. DOI: https://doi.org/10.14341/2071-8713-5065
Zagrebaeva OU. Interconnection of serotonin with metabolic status in obese children. Ukrainskyi zhurnal dytiachoi endokrynolohii. 2016; 2: 18-23.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.